Literature DB >> 12843446

Ribonuclease protection.

J L Thorvaldsen1, M S Bartolomei.   

Abstract

The ribonuclease protection assay (RPA) is a sensitive technique for the analysis of total cellular RNA. It involves generating a specific antisense riboprobe, hybridizing the probe to total RNA, removing unprotected RNA by RNases, and finally isolating and analyzing the protected RNA on a denaturing gel. Although the RPA is somewhat more labor-intensive than Northern analysis, it has the advantage of being more sensitive (as little as 0.1 pg of target RNA can be detected with ideal hybridization conditions). RPAs are also more tolerant of partially degraded RNA (provided the area that is protected is intact). Although RPAs are not as sensitive as polymerase chain reaction (PCR)-based RNA analyses, the target RNA is analyzed directly; a reverse transcription step is not required. Finally, the RPA is quantitative as long as the probe is in excess. More important for the study of imprinted genes, the RPA can be designed to detect allele-specific expression of the target gene of interest.

Mesh:

Substances:

Year:  2001        PMID: 12843446     DOI: 10.1385/1-59259-211-2:133

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  Developmental profile of H19 differentially methylated domain (DMD) deletion alleles reveals multiple roles of the DMD in regulating allelic expression and DNA methylation at the imprinted H19/Igf2 locus.

Authors:  Joanne L Thorvaldsen; Andrew M Fedoriw; Son Nguyen; Marisa S Bartolomei
Journal:  Mol Cell Biol       Date:  2006-02       Impact factor: 4.272

2.  Evidence for transcript networks composed of chimeric RNAs in human cells.

Authors:  Sarah Djebali; Julien Lagarde; Philipp Kapranov; Vincent Lacroix; Christelle Borel; Jonathan M Mudge; Cédric Howald; Sylvain Foissac; Catherine Ucla; Jacqueline Chrast; Paolo Ribeca; David Martin; Ryan R Murray; Xinping Yang; Lila Ghamsari; Chenwei Lin; Ian Bell; Erica Dumais; Jorg Drenkow; Michael L Tress; Josep Lluís Gelpí; Modesto Orozco; Alfonso Valencia; Nynke L van Berkum; Bryan R Lajoie; Marc Vidal; John Stamatoyannopoulos; Philippe Batut; Alex Dobin; Jennifer Harrow; Tim Hubbard; Job Dekker; Adam Frankish; Kourosh Salehi-Ashtiani; Alexandre Reymond; Stylianos E Antonarakis; Roderic Guigó; Thomas R Gingeras
Journal:  PLoS One       Date:  2012-01-04       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.